Late Night Market Recap

 Night.Owl
 
  Night.Owl
 
Follow  Message
 
 
 
Night.Owl masters market recaps, offering sharp analysis that uncovers hidden patterns and key moves. Stay ahead with Night.Owl’s expert insights.
 

•  11 Dec 2025
 

•   ADBE  
   
  0.00%
•   ALAB  
   
  0.00%
•   ANET  
   
  0.00%
•   AVGO  
   
  0.00%
•   DIS  
   
  0.00%

$F Ford Motor was in focus after South Korea SK On confirmed it will dissolve their US battery joint venture, a partnership built on an $11.4 billion investment. SK On is reallocating capital toward new growth paths while Ford reassesses long-range EV capacity planning. The news drove heavy trading interest as investors interpreted the move as strategic repositioning rather than operational strain.

$AVGO Broadcom generated significant after-hours attention following its fiscal Q4 results, which beat on both revenue and earnings while reaffirming strong AI-chip and custom ASIC momentum. Despite the company projecting that AI chip sales will double, sentiment was mixed as expectations had risen sharply ahead of the print. Analysts maintained bullish long-term views anchored in AI-infrastructure scale-out.

$KO Coca-Cola announcement that Henrique Braun will assume the CEO role in March 2026 set the tone for the session. Investors evaluated the leadership transition through the lens of global execution consistency and dividend resilience. The KO versus PEP income-stock comparison resurfaced as traders digested the implications of new executive leadership.

$LYFT Lyft drew renewed interest after Wells Fargo lifted its price target to 26, citing a strong US operating outlook. While questions remain around international diversification, traders leaned into improving fundamentals and the elevated short-interest setup.

$DIS Disney was one of the standout names as the market reacted to its $1 billion investment in OpenAI and a landmark content-licensing partnership enabling iconic Disney characters to be used within the Sora AI video platform. Options activity surged as investors framed the deal as a meaningful step in AI-native content monetization.

$ADBE Adobe gained attention after posting a strong Q4 earnings beat supported by continued acceleration in AI-driven ARR. Although some analysts trimmed forward estimates due to concerns about slower FY26 growth, sentiment stayed constructive thanks to Adobe sticky product ecosystem and significant enterprise penetration.

$JNJ Johnson & Johnson benefited from fresh enthusiasm after ASH 2025 delivered compelling new multiple-myeloma results. Guggenheim reiterated its Buy rating, emphasizing JNJ innovation cycle, durable cash flow, and diversified pharma pipeline.

$MRNA Moderna extended its recent momentum as news of a 1.5 billion five-year loan from Ares Management continued to circulate. Rising short interest and anticipation ahead of strategic updates kept traders active, and commentary from company leadership on US competitiveness in vaccine technology added broader industry context.

$MO Altria's announcement that Sal Mancuso will assume the CEO position signaled governance continuity. Investors interpreted the leadership change as steady rather than transformative, keeping sentiment stable.

$ANET Arista Networks gained traction as traders revisited the positioning in AI-driven data center expansion. Notable whale activity in the options market signaled rising institutional expectations into 2026, even as analysts maintained neutral ratings.

$LULU Lululemon strong Q3 results, highlighted by earnings and revenue beats, were tempered by the announcement that CEO Calvin McDonald plans to step down. Early optimism around financial performance gave way to measured positioning as investors assessed upcoming leadership changes.

$ALAB Astera Labs outperformed as Wall Street boosted price targets and highlighted accelerating demand across AI infrastructure. The year-over-year revenue doubling reinforced its relevance in hyperscale connectivity solutions and broadened institutional interest.

$GILD Gilead attracted attention on promising oncology updates tied to multiple-myeloma breakthroughs, complemented by supportive valuation metrics. Trading activity also reflected positioning ahead of the next dividend cycle.

$LLY Eli Lilly advanced following strong Phase 3 results for retatrutide, which demonstrated substantial weight loss and measurable improvement in osteoarthritis pain. With Mounjaro added to China national health insurance program, long-term growth prospects across international metabolic markets remained firmly in focus.

View All Headlines